Press Releases

INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights

Posted on May 10, 2023

New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023

Posted on May 8, 2023

INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference

Posted on May 5, 2023

INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023

Posted on April 28, 2023

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

Posted on April 27, 2023

European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO’s Application for Orphan Drug Designation for INO-3107

Posted on April 26, 2023

Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023

Posted on April 17, 2023

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023

Posted on April 12, 2023

INOVIO Reports Inducement Grant Under Inducement Plan

Posted on April 3, 2023

INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

Posted on March 3, 2023

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.